Baxter International Inc. officially opened its first advanced recombinant biologic facility in Singapore. The company also announced expansion plans for a new recombinant protein processing suite. The facility and new investment will have created 450 biopharmaceutical jobs by 2015 in Singapore.
Baxter said in a press release that the current suite supports the processing of ADVATE [Antihemophilic Factor (Recombinant)], the market leading full-length recombinant factor VIII (rFVIII) worldwide for the treatment of patients with hemophilia A. The second suite will initially process RIXUBIS [Coagulation Factor IX (Recombinant)]2, a recombinant factor IX (rFIX) protein for the treatment of adults with hemophilia B and, when operational, will be the primary global commercial processing facility. It will also support production of the company’s investigational extended half-life recombinant FVIII treatment BAX 855 upon regulatory approval.
Speaking at the opening of the facility, Jean-Luc Butel, corporate vice president and president of Baxter's international operations, said, "As a long-standing, established leader in the global hemophilia community, Baxter has focused efforts on improving standards of care for people with hemophilia. The opening of the Singapore facility is a reflection of the company's commitment."
Read the full press release